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OBJECTIVE: To assess the costs of COPD from the 
societal perspective in Germany. METHODS: The 1-year
resource use associated with COPD was documented ret-
rospectively for the year 2001, based on medical charts
of 321 patients selected at random and suffering from
mild, moderate, or severe COPD. Costs were assessed for
each stage of disease severity and weighted to total costs
using the relative frequency of COPD severity stages
derived from an epidemiological pre-study. RESULTS:
Annual COPD-related costs per patient and year were
€3027 from the societal perspective. Main cost drivers
were hospitalisations, accounting for 26% of total costs,
followed by medication (23%) and early retirement
(17%). Costs increased with disease severity from €2364
(mild) to €6585 (severe). Mainly, the COPD-related
expenditures for hospitalisation, nursing and for early
retirement increased with the disease severity. Forty
percent of the costs were caused by COPD exacerbations
while the other 60% were due to the basic treatment of
COPD. The average costs per exacerbation amounted to
€412. Large differences were observed between the costs
of an exacerbation, which required in-hospital treatment
and those, which could be treated in the outpatient setting
only. Following the results of our analysis, the main part
of the costs (64%) were covered by the sickness funds.
Assuming COPD prevalence rates between 3.3% and 5%,
annual costs of COPD range between €8.21 billion and
€12.44 billion from the societal perspective. CONCLU-
SION: COPD causes a signiﬁcant economic burden in
Germany. The costs are mainly determined by the disease
severity and the appearance of exacerbations, which
require hospitalisations. Thus, it is extremely important
not only for the patients’ well-being but also from an eco-
nomic point of view to prevent COPD and to identify
optimal COPD treatments, which are able to reduce
disease progression and avoid costly exacerbations.
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COST OFFSETS FROM PRESCRIPTION
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Numerous studies have shown that appropriate drug use
can reduce hospitalization and other more expensive ther-
apies. Some commentators argue that these ﬁndings imply
that drug coverage pays for itself. As appealing as this
conclusion may be, there is no credible research literature
to support it. OBJECTIVES: This study is one of a series
to assess the extent to which extending drug coverage to
all US Medicare beneﬁciaries would result in cost savings
elsewhere in the Medicare budget. Using data from the
Medicare Current Beneﬁciary Survey (1996–2000), we
assess each link in the causal chain between drug cover-
age and other health care spending for a sample of ben-
eﬁciaries diagnosed with COPD. We selected COPD for
3 reasons: it is a prevalent problem affecting about 16%
of the population over 65, acute exacerbations of the
disease are sensitive to medication therapy, and there are
reports that under-medication may be associated with
lack of prescription coverage. We compared expenditures
for COPD patients with and without drug coverage con-
trolling for selection effects and other confounders using
two METHODS: 1) A general linear regression model
with a gamma distribution and a log link function, and
2) by weighting sample observations based on propensity
scores. The propensity scores were derived from a logit
regression of prescription coverage status on a rich set of
sociodemographic variables and a medical expenditure
risk adjuster speciﬁcally designed for use with Medicare
claims. Our results indicate that for every 10% increase
in the generosity of drug coverage, drug spending rises
between 3% and 4%, while inpatiet hospital and physi-
cian spending each decline by 3% to 4%. The generaliz-
ability of these results to older people with other chronic
conditions is discussed.
RESPIRATORY DISORDERS—Clinical Outcomes
Studies
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DO RESPIRATORY DRUGS REDUCE HOSPITAL
ADMISSIONS? AN ECOLOGICAL STUDY
CARRIED OUT IN MODENA, ITALY,TO
INVESTIGATE DISTRICTS’ VARIABILITY
Maltoni S1, Marata AM1, Brunetti M1, Menna A1,Violante A1,
Fellin G2, Campomori A1, Magrini N1
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OBJECTIVES: To verify if the variability observed in pre-
scription of respiratory drugs is related to a different 
hospital admission rate for respiratory diseases (asthma
and chronic obstructive pulmonary disease, COPD).
METHODS: We carried out an ecological study in the
Local Health Unit of Modena (632,000 inhabitants, 7
districts, 517 general practitioners—GPs- and 40 primary
care groups). Every GP, primary care group and district
receives two different reports quarterly, both weighted for
age and sex. The ﬁrst report is on drugs prescribed and
reimbursed by the National Health System (NHS) and the
second one on NHS hospital admissions. For drug con-
sumption, data are retrieved from the 157 retail pharma-
cies in Modena. The chosen indicators are per person
